Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

Overview
Date Founded

2017

Headquarters

21900 Burbank Boulevard,3rd Floor,Woodland Hills, CA 91367

Type of Company

Public

Employees (Worldwide)

148

Industries

Biotechnology
Pharmaceuticals
Medical Support Services
Hospitals & Patient Services

Company Description

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Contact Data
Trying to get in touch with decision makers at Iovance Biotherapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial & Accounting Officer

General Counsel

Chief Medical Officer

Vice President, Corporate Development

Chief Executive Officer & Director

Commercial Lines Account Executive

Medical Director

Vice President

Board of Directors

Venture Partner at OrbiMed Advisors LLC

Founder at McPeak & Associates

President, Chief Executive Officer & Director at Turning Point Therapeutics, Inc.

Founder at Actin Biomed LLC

President & Chief Executive Officer at Iovance Biotherapeutics, Inc.

Former Assistant Secretary at Rigel Pharmaceuticals, Inc.

Founder at Quogue Capital LLC

President, Chief Executive Officer & Director at Redpin Therapeutics, Inc.

Paths to Iovance Biotherapeutics, Inc.
Potential Connections via
Relationship Science
You
Iovance Biotherapeutics, Inc.
Owners & Shareholders
Details Hidden

AVCAP aims to achieve attractive returns with moderate risk. The firm invests primarily in the equity, debt and associated derivatives of companies operating in the life sciences sector and related industries with a focus on publicly traded, and late-stage private biotechnology companies.

Details Hidden

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across our strategies.

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Recent Transactions
Details Hidden

Iovance Biotherapeutics, Inc. issued USD Common Stock

Details Hidden

Iovance Biotherapeutics, Inc. issued USD Common Stock

Details Hidden

Iovance Biotherapeutics, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onIovance Biotherapeutics, Inc. issued USD Common Stock

Escrow Agent

Advised onIovance Biotherapeutics, Inc. issued USD Common Stock

Auditor

Advised onIovance Biotherapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onIovance Biotherapeutics, Inc. issued USD Common Stock

Managing Director

Advised onIovance Biotherapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onIovance Biotherapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Chief Cellular Therapy Officer at Nurix Therapeutics, Inc.

Advisor

Head of Investor Relations at Sutro Biopharma, Inc.

Advisor

Chief Financial Officer at GT Biopharma, Inc.

Key Stats and Financials As of 2019
Market Capitalization
$5.37B
Total Enterprise Value
$3.15B
Earnings Per Share
$-1.59
Revenue
$0
TEVNet Income
-15.92x
Debt TEV
0x
Total Debt
$11.5M
EBITDA
$-199M
Total Equity
$299M
Net Profit
$-198M
Non-Profit Donations & Grants
Suppliers
Lonza Group AG Pharmaceuticals | Basel, Che

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

University of Texas - MD Anderson Cancer Center Medical Support Services | Houston, TX

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Seagen Inc. Pharmaceuticals - Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Iovance Biotherapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Iovance Biotherapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Iovance Biotherapeutics, Inc..